keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/28329919/-chemotherapy-for-biliary-tract-cancer
#1
REVIEW
Sang Myung Woo
The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder. BTCs are aggressive tumors with limited treatment options and poor overall survival. Currently, surgery remains to be the only potentially curative treatment, and most patients develop recurrence. For advanced tumors, only limited effective treatment modalities exist today. Gemcitabine plus cisplatin is considered as a standard option for advanced biliary cancer...
March 25, 2017: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/28329488/capecitabine-induced-lichenoid-drug-eruption-a-case-report
#2
Jeff R Gehlhausen, Matthew B Strausburg, Mouhammad Aouthmany, Terrence M Katona, Matthew J Turner
Capecitabine is a 5-fluorouracil basedchemotherapeutic drug widely used in the treatmentof solid tumors, especially colorectal and breast. Someof the most common side effects of capecitabine arecutaneous in nature, including hand-foot syndrome(palmar-plantar erythrodysesthesia). Several reports inthe literature link capecitabine use with photosensitivelichenoid eruptions. Herein, we present a case ofcapecitabine-induced lichenoid eruption in an elderlyfemale with metastatic breast cancer and discuss ourfindings in relationship to previously reported cases ofthis and other capecitabine-induced skin pathologies...
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28327898/adherence-to-capecitabine-in-preoperative-treatment-of-stage-ii-and-iii-rectal-cancer-do-we-need-to-worry
#3
R Font, J A Espinas, L Layos, M Martinez Villacampa, J Capdevila, M Tobeña, A Pisa, C Pericay, C Lezcano, E Fort, I Cardona, N Berga, J Solà, J M Borras
Background: : Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with rectal cancer, but little is known about adherence to this therapy. Patients and methods: : Prospective, multicentre observational study in six hospitals in metropolitan Barcelona (Spain), in patients with stage II and III rectal cancer. Assessment of adherence was based on the medical report in the clinical history, a patient questionnaire and a pill count in the pharmacy service upon finalization of treatment...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28306672/radiotherapy-chemotherapy-and-atherosclerosis
#4
San S Min, Anthony S Wierzbicki
PURPOSE OF REVIEW: This article reviews the effects of radiotherapy and chemotherapy in promoting the progression of atherosclerosis in patients with cancer. RECENT FINDINGS: Radiotherapy is associated with an increase in the incidence of atherosclerosis with the effects being related to the site of irradiation and dose of radiotherapy. Cranial irradiation is associated with dyslipidaemia and the metabolic syndrome secondary to effect on growth hormone secretion...
March 16, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/28303435/systemic-combination-chemotherapy-in-elderly-pancreatic-cancer-a-review
#5
REVIEW
Gwenalyn Garcia, Marcel Odaimi
PURPOSE: In recent years, significant progress in survival has been achieved using systemic combination chemotherapy in patients with pancreatic cancer. However, the elderly are largely underrepresented in clinical trials, and gains made from these may not necessarily apply to this important subgroup of patients. We review the currently available data regarding contemporary combination chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, nanoliposomal irinotecan plus 5-fluorouracil and leucovorin, and gemcitabine plus capecitabine, in elderly pancreatic cancer patients...
March 16, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28303362/phase-i-ii-study-of-a-combination-of-capecitabine-cisplatin-and-intraperitoneal-docetaxel-xp-id-in-advanced-gastric-cancer-patients-with-peritoneal-metastasis
#6
Hyungwoo Cho, Min-Hee Ryu, Kyu-Pyo Kim, Baek-Yeol Ryoo, Sook Ryun Park, Bum Soo Kim, In-Seob Lee, Hee-Sung Kim, Moon-Won Yoo, Jeong Hwan Yook, Seong Tae Oh, Byung Sik Kim, Yoon-Koo Kang
BACKGROUND: This study was conducted to determine the recommended dose (RD) of intraperitoneal docetaxel (ID) in combination with systemic capecitabine and cisplatin (XP) and to evaluate its efficacy and safety at the RD in advanced gastric cancer (AGC) patients with peritoneal metastasis. METHODS: AGC patients with peritoneal metastasis received XP ID, which consists of 937.5 mg/m(2) of capecitabine twice daily on days 1-14, 60 mg/m(2) of intravenous cisplatin on day 1, and intraperitoneal docetaxel at 3 different dose levels (60, 80, or 100 mg/m(2)) on day 1, every 3 weeks...
March 16, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28286287/incidence-of-capecitabine-related-cardiotoxicity-in-different-treatment-schedules-of-metastatic-colorectal-cancer-a-retrospective-analysis-of-the-cairo-studies-of-the-dutch-colorectal-cancer-group
#7
Johannes J M Kwakman, Lieke H J Simkens, Linda Mol, Wouter E M Kok, Miriam Koopman, Cornelis J A Punt
BACKGROUND: The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes serious adverse events. We conducted a retrospective analysis of the incidence and severity of capecitabine-related cardiotoxicity in different regimens in the treatment of metastatic colorectal cancer in three randomised phase 3 studies. METHODS: We used data of cardiac events reported in the CAIRO, CAIRO2 and CAIRO3 studies of the Dutch Colorectal Cancer Group (DCCG) and analysed the incidence and severity of cardiac events in the different treatment regimens of the trials which all included the use of capecitabine...
March 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28285948/premedication-with-fast-acting-oxycodone-hydrochloride-hydrate-effectively-reduced-oxaliplatin-induced-severe-vascular-pain
#8
Sayaka Nagao, Makoto Furihata, Kazushi Fukagawa, Tadashi Furihata, Yuki Matsuhashi, Tomonori Wada
Oxaliplatin is a platinum-based chemotherapeutic agent that holds a prominent position in the treatment of colorectal and gastric cancers. However, severe oxaliplatin-related vascular pain can be problematic for patients. Here we describe seven patients who experienced severe vascular pain caused by oxaliplatin administration. All seven patients were treated with capecitabine and oxaliplatin or capecitabine plus oxaliplatin with bevacizumab as an adjuvant or a treatment for recurrent colorectal cancer, respectively...
March 10, 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28284574/comparison-of-5-fu-based-and-capecitabine-based-neoadjuvant-chemoradiotherapy-in-patients-with-rectal-cancer-a-meta-analysis
#9
Xiang-Cai Zou, Qiwen Wang, Jimin Zhang
INTRODUCTION: The inconvenience of using infusion therapies resulted in the development of capecitabine (CA), an oral fluoropyrimidine. In this meta-analysis, we evaluated 10 studies that compared the efficacy and safety of an oral CA-based regimen with those of a continuous infusion 5-fluorouracil (5-FU) regimen for neoadjuvant chemoradiotherapy in patients with rectal cancer. MATERIALS AND METHODS: The databases searched included Medline, Cochrane, EMBASE, and Google Scholar (until August 31, 2016)...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28281917/brd4-inhibitor-ibet-upregulates-p27kip-cip-protein-stability-in-neuroendocrine-tumor-cells
#10
Lei Wang, Smita Matkar, Gengchen Xie, Chiying An, Xin He, Xiangchen Kong, Xiuheng Liu, Xianxin Hua
The prevalence of neuroendocrine tumors (NETs) has recently been increasing. Although various drugs such as Octreotide and its analogs show certain efficacy, NETs in many patients progress and metastasize. It is desirable to develop new interventions to improve the therapy. Here we show that human neuroendocrine tumor BON cells are resistant to several drugs commonly used for NET therapy, including Octreotide that activates somatostatin receptor-induced anti-proliferation, and Capecitabine and Temozolimide that damage DNA...
March 10, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28281215/neoadjuvant-treatment-for-locally-advanced-rectal-cancer-new-concepts-in-clinical-trial-design
#11
REVIEW
Nitesh Rana, A Bapsi Chakravarthy, Lisa A Kachnic
Treatment for locally advanced rectal cancer has evolved from surgery alone to surgery plus adjuvant therapy. Preoperative 5-fluorouracil- or capecitabine-based chemoradiation with standard fractionated radiation, surgery utilizing total mesorectal excision, and further chemotherapy has become the standard of care in the USA. Preoperative adjuvant chemoradiation treatment sequencing has allowed for decreased toxicity, more sphincter-sparing surgery, and improved local control rates as compared to delivering the chemoradiation postoperatively...
February 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28280649/first-case-of-foot-drop-associated-with-capecitabine-in-a-patient-with-thymidylate-synthase-polymorphism
#12
Andrew B Wilks, Muhammad W Saif
Capecitabine, an oral prodrug of 5-FU, has been approved by the FDA for use in patients with breast and colon cancers. In addition, capecitabine is commonly used in patients with other malignancies such as pancreatic, gastroesophageal, and hepatobiliary tract cancers. Though cerebellar toxicity is a rare but well-known side effect of intravenous 5-FU therapy, peripheral neuropathy with capecitabine has only been described in rare cases. In this case report, we describe a 79-year-old patient with locally advanced adenocarcinoma of the pancreas undergoing chemoradiation therapy with capecitabine who developed peripheral sensorimotor neuropathy...
January 24, 2017: Curēus
https://www.readbyqxmd.com/read/28280620/potential-actionable-targets-in-appendiceal-cancer-detected-by-immunohistochemistry-fluorescent-in-situ-hybridization-and-mutational-analysis
#13
Erkut Borazanci, Sherri Z Millis, Jeffery Kimbrough, Nancy Doll, Daniel Von Hoff, Ramesh K Ramanathan
BACKGROUND: Appendiceal cancers are rare and consist of carcinoid, mucocele, pseudomyxoma peritonei (PMP), goblet cell carcinoma, lymphoma, and adenocarcinoma histologies. Current treatment involves surgical resection or debulking, but no standard exists for adjuvant chemotherapy or treatment for metastatic disease. METHODS: Samples were identified from approximately 60,000 global tumors analyzed at a referral molecular profiling CLIA-certified laboratory. A total of 588 samples with appendix primary tumor sites were identified (male/female ratio of 2:3; mean age =55)...
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28279465/the-asian-perspective-on-the-surgical-and-adjuvant-management-of-esophagogastric-cancer
#14
REVIEW
Yukinori Kurokawa, Mitsuru Sasako
In East Asia, D2 dissection has been routine surgical procedure for curable advanced gastric cancer. More extended surgery than D2 is reserved for borderline resectable disease with extended nodal metastasis. The addition of radiation therapy to adjuvant chemotherapy failed to improve the outcome after D2 dissection. Because many patients are diagnosed in East Asia with early-stage disease, postoperative adjuvant chemotherapy is preferred, and S-1 monotherapy or capecitabine-oxaliplatin is standard care. Neoadjuvant chemotherapy may be preferred for stage III tumors; for borderline resectable tumors, preoperative chemotherapy is under study given the limitations of postoperative adjuvant chemotherapy in high-risk patients...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28279170/patients-with-pathological-stage-n2-rectal-cancer-treated-with-early-adjuvant-chemotherapy-have-a-lower-treatment-failure-rate
#15
Yan-Ru Feng, Jing Jin, Hua Ren, Xin Wang, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Xin-Fan Liu, Hui Fang, Zi-Hao Yu, Ye-Xiong Li
BACKGROUND: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence. METHODS: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT) group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant chemotherapy...
March 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28277833/capecitabine-in-locally-advanced-anal-cancer-do-we-need-randomised-evidence
#16
Li Chia Chong, Tabitha Healey, Tony Michele, Timothy J Price
Standard treatment for locally advanced anal cancer is chemoradiotherapy with mitomycin C and fluorouracil. However, infusional fluorouracil requires central venous catheter placement potentiating risk of infection and thrombosis. Capecitabine which is an oral tumor activated fluoropyrimidine carbamate is an established treatment alternative to infusional fluorouracil for patients with gastrointestinal cancers. Areas covered: This review examines and discusses the current evidence for substitution of Capecitabine for infusional fluorouracil in locally advanced anal cancer...
March 13, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28277030/cost-minimization-analysis-of-capecitabine-versus-5-fluorouracil-based-treatment-for-gastric-cancer-patients-in-hong-kong
#17
Keary R Zhou, Ashley Cheng, W T Ng, T Y Kwok, Elton Y P Yip, Rosa Yao, P Y Leung, V W Y Lee
BACKGROUND: EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the healthcare and societal perspectives. It should be noted that, while FOLFOX4 is routinely administered in an outpatient setting in North America and Europe, inpatient setting is adopted in Hong Kong instead, incurring hospitalization cost as a result...
March 2, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28274890/metronomic-chemotherapy-in-metastatic-colorectal-cancer
#18
In Sook Woo, Yun Hwa Jung
Overall survival and quality of life of patients with metastatic colorectal cancer (mCRC) have improved due to the development of standard systemic treatment. However, many patients are still suffering from the eventual progression of cancer, treatment-related toxicities, and the economic burden of new drugs. Salvage or maintenance therapy, which consistently controls or stabilizes tumor progression without debilitating quality of life, is warranted. Recently, metronomic capecitabine maintenance therapy after disease control using conventional chemotherapy with maximal tolerated doses has demonstrated beneficial results in a phase III trial...
March 6, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28267212/perioperative-chemotherapy-versus-neoadjuvant-chemoradiotherapy-for-esophageal-or-gej-adenocarcinoma-a-propensity-score-matched-analysis-comparing-toxicity-pathologic-outcome-and-survival
#19
Lucas Goense, Pieter C van der Sluis, Peter S N van Rossum, Sylvia van der Horst, Gert J Meijer, Nadia Haj Mohammad, Marco van Vulpen, Stella Mook, Jelle P Ruurda, Richard van Hillegersberg
OBJECTIVES: To evaluate toxicity, pathologic outcome, and survival after perioperative chemotherapy (pCT) compared to neoadjuvant chemoradiotherapy (nCRT) followed by surgery for patients with resectable esophageal or gastroesophageal junction (GEJ) adenocarcinoma. METHODS: Consecutive patients with resectable esophageal or GEJ adenocarcinoma who underwent pCT (epirubicin, cisplatin, and capecitabine) or nCRT (paclitaxel, carboplatin, and 41.4 Gy) followed by surgery in a tertiary referral center in the Netherlands were compared...
March 7, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28263201/a-systematic-review-and-pooled-analysis-of-retrospective-series-of-eribulin-in-metastatic-breast-cancer
#20
Ioannis A Voutsadakis
Eribulin is one of the newer chemotherapeutic agents approved for use in later line treatment of patients with metastatic breast cancer. Phase III studies have shown a useful clinical response rate for eribulin as well as equivalence to another commonly used drug in metastatic breast cancer, capecitabine. Nevertheless, whether this clinical value observed in trial patients is maintained in patients seen in clinical oncology practice, outside trials remains a question. Several series published over the last few years sought to answer this question...
March 3, 2017: Anti-cancer Drugs
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"